
Andrew J Lee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7504958/publications.pdf Version: 2024-02-01



ANDREWILEE

0

#	ARTICLE	IF	CITATIONS
1	Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factors. Journal of Medical Genetics, 2022, 59, 632-643.	1.5	33
2	Cancer Risks Associated With <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variants. Journal of Clinical Oncology, 2022, 40, 1529-1541.	0.8	90
3	Predicting the Likelihood of Carrying a <i>BRCA1</i> or <i>BRCA2</i> Mutation in Asian Patients With Breast Cancer. Journal of Clinical Oncology, 2022, 40, 1542-1551.	0.8	14
4	Comparative validation of the BOADICEA and Tyrer-Cuzick breast cancer risk models incorporating classical risk factors and polygenic risk in a population-based prospective cohort of women of European ancestry. Breast Cancer Research, 2021, 23, 22.	2.2	49
5	Prospective Evaluation of the Addition of Polygenic Risk Scores to Breast Cancer Risk Models. JNCI Cancer Spectrum, 2021, 5, pkab021.	1.4	19
6	Potential of polygenic risk scores for improving population estimates of women's breast cancer genetic risks. Genetics in Medicine, 2021, 23, 2114-2121.	1.1	9
7	Should Age-Dependent Absolute Risk Thresholds Be Used for Risk Stratification in Risk-Stratified Breast Cancer Screening?. Journal of Personalized Medicine, 2021, 11, 916.	1.1	8
8	Performance of Breast Cancer Polygenic Risk Scores in 760 Female <i>CHEK2</i> Germline Mutation Carriers. Journal of the National Cancer Institute, 2021, 113, 893-899.	3.0	21
9	CanRisk Tool—A Web Interface for the Prediction of Breast and Ovarian Cancer Risk and the Likelihood of Carrying Genetic Pathogenic Variants. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 469-473.	1.1	98
10	Prospective Evaluation over 15 Years of Six Breast Cancer Risk Models. Cancers, 2021, 13, 5194.	1.7	7
11	Cancer Risks Associated With Germline <i>PALB2</i> Pathogenic Variants: An International Study of 524 Families. Journal of Clinical Oncology, 2020, 38, 674-685.	0.8	270
12	Population Study of Ovarian Cancer Risk Prediction for Targeted Screening and Prevention. Cancers, 2020, 12, 1241.	1.7	19
13	Evaluating clinician acceptability of the prototype CanRisk tool for predicting risk of breast and ovarian cancer: A multi-methods study. PLoS ONE, 2020, 15, e0229999.	1.1	40
14	Validation of the BOADICEA model and a 313-variant polygenic risk score for breast cancer risk prediction in a Dutch prospective cohort. Genetics in Medicine, 2020, 22, 1803-1811.	1.1	49
15	Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in <i>RAD51C</i> and <i>RAD51D</i> . Journal of the National Cancer Institute, 2020, 112, 1242-1250.	3.0	106
16	Title is missing!. , 2020, 15, e0229999.		0
17	Title is missing!. , 2020, 15, e0229999.		0

Andrew J Lee

#	Article	IF	CITATIONS
19	Title is missing!. , 2020, 15, e0229999.		Ο
20	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. American Journal of Human Genetics, 2019, 104, 21-34.	2.6	711
21	Homeobox B13 G84E Mutation and Prostate Cancer Risk. European Urology, 2019, 75, 834-845.	0.9	28
22	BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. Genetics in Medicine, 2019, 21, 1708-1718.	1.1	415
23	Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women. Journal of the National Cancer Institute, 2018, 110, 714-725.	3.0	138
24	pedigreejs: a web-based graphical pedigree editor. Bioinformatics, 2018, 34, 1069-1071.	1.8	9
25	Evaluation of polygenic risk scores for ovarian cancer risk prediction in a prospective cohort study. Journal of Medical Genetics, 2018, 55, 546-554.	1.5	38
26	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	9.4	356
27	Association analysis identifies 65 new breast cancer risk loci. Nature, 2017, 551, 92-94.	13.7	1,099
28	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	9.4	289
29	Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 404-412.	1.1	341
30	The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 126-135.	1.1	278
31	Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2017, 109, .	3.0	242
32	Prediction of Breast and Prostate Cancer Risks in Male <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers Using Polygenic Risk Scores. Journal of Clinical Oncology, 2017, 35, 2240-2250.	0.8	152
33	Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model. Genetics in Medicine, 2016, 18, 1190-1198.	1.1	80
34	Polygenic risk score is associated with increased disease risk in 52 Finnish breast cancer families. Breast Cancer Research and Treatment, 2016, 158, 463-469.	1.1	24
35	Age- and Tumor Subtype–Specific Breast Cancer Risk Estimates for <i>CHEK2</i> *1100delC Carriers. Journal of Clinical Oncology, 2016, 34, 2750-2760.	0.8	152
36	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	9.4	125

Andrew J Lee

#	Article	IF	CITATIONS
37	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research, 2015, 17, 61.	2.2	26
38	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	9.4	221
39	A risk prediction algorithm for ovarian cancer incorporating <i>BRCA1, BRCA2</i> , common alleles and other familial effects. Journal of Medical Genetics, 2015, 52, 465-475.	1.5	52
40	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 308-316.	1.1	22
41	DNA Clycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genetics, 2014, 10, e1004256.	1.5	47
42	Breast-Cancer Risk in Families with Mutations in <i>PALB2</i> . New England Journal of Medicine, 2014, 371, 497-506.	13.9	745
43	The PROFILE feasibility study: Genetic prostate cancer risk stratification for targeted screening Journal of Clinical Oncology, 2014, 32, 22-22.	0.8	Ο
44	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nature Genetics, 2013, 45, 353-361.	9.4	960
45	Profile study: Genetic prostate cancer risk stratification for targeted screening Journal of Clinical Oncology, 2013, 31, 5054-5054.	0.8	0